| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | April 1, 2026 4:00 P.M. |
| Form: | S-1 | ||||||
| |||||||
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/26/2026 | Overweight | Cantor Fitzgerald | |
| 2/19/2026 | $10.00 | Neutral → Outperform | Mizuho |
Management to be Joined by Two Clinical Leaders in the Breast Cancer Field Expected to Complete Enrollment in Ongoing ELAINE-3 Phase 3 Registrational Study of Lasofoxifene in Metastatic Breast Cancer in 4Q26 with Data Expected in 2H27 Webinar Event on Wednesday, April 29, 2026, at 12:00 p.m. ET BOTHELL, Wash., April 23, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ:LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today announced that it will host a virtual Key Opinion Leader event with two leading physician experts in the breast cancer field to discuss the current and evolving treatment la
BOTHELL, Wash., April 21, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ:LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, attended the American Association for Cancer Research Annual Meeting 2026 (AACR26), where independent researchers at Virginia Commonwealth University's Massey Comprehensive Cancer Center presented nonclinical data on lasofoxifene, including its potential for a bone protective role in metastatic breast cancer.1 "We are delighted to learn the findings of this independent research at AACR26, attended by an audience of the world's leading oncology researchers. We believe these
Acquired License to Phase 3 Lasofoxifene Development Program of Novel Selective Estrogen Receptor Modulator (SERM), a Potential Multi-Billion Dollar Opportunity as Treatment Option for Breast Cancer Patients with ESR1-Mutations Received Gross Proceeds of $90 Million in Private Placement Financing of Common Stock and Warrants with Cash-Exercisable Warrants Potentially Providing up to an Additional $146 Million to Support Development of Lasofoxifene Through Key Clinical and Regulatory Milestones Expect to Complete Enrollment of Phase 3 Clinical Trial of Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer in 4Q 2026 with Topline Data Anticipated in 2H 2027
4 - LeonaBio, Inc. (0001620463) (Issuer)
4 - LeonaBio, Inc. (0001620463) (Issuer)
4 - LeonaBio, Inc. (0001620463) (Issuer)
Cantor Fitzgerald initiated coverage of LeonaBio with a rating of Overweight
Mizuho upgraded LeonaBio from Neutral to Outperform and set a new price target of $10.00
EFFECT - LeonaBio, Inc. (0001620463) (Filer)
EFFECT - LeonaBio, Inc. (0001620463) (Filer)
424B3 - LeonaBio, Inc. (0001620463) (Filer)
BOTHELL, Wash., Feb. 03, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ:LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today announced the appointment of Mark F. Kubik as Chief Business Officer. In this role, Mr. Kubik will lead LeonaBio's business development strategy and execution, with responsibility for licensing, partnership strategy, and corporate development initiatives. Mr. Kubik previously served as a strategic consultant to LeonaBio, where he played an instrumental role in the transformational transaction announced in December 2025, in which LeonaBio acquired rights to the Phase 3